Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with or without olaparib plus carboplatin and paclitaxel for first-line advanced or recurrent endometrial cancer
jRCT2080225349Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of durvalumab and olaparib in endometrial cancer (EC) (3 arms), sponsored by AstraZeneca. Started Aug 2020; status: completed.
02
Drugs
durvalumabolaparib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on jRCT2080225349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225349.